| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
5 analysts have shared their evaluations of Mersana Therapeutics (NASDAQ:MRSN) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $6.6, a high estimate of $9.00, and a low estimate of $5.00. Witnessing a positive shift, the current average has risen by 65.0% from the previous average price target of $4.00.
The analysis of recent analyst actions sheds light on the perception of Mersana Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brian Cheng | JP Morgan | Announces | Neutral | $5.00 | - |
| David Nierengarten | Wedbush | Raises | Outperform | $7.00 | $2.00 |
| Asthika Goonewardene | Truist Securities | Maintains | Buy | $9.00 | $9.00 |
| Colleen Kusy | Baird | Raises | Neutral | $5.00 | $1.00 |
| Michael Schmidt | Guggenheim | Announces | Buy | $7.00 | - |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Mersana Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Mersana Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Decline in Revenue: Over the 3 months period, Mersana Therapeutics faced challenges, resulting in a decline of approximately -27.14% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Mersana Therapeutics's net margin excels beyond industry benchmarks, reaching -182.64%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Mersana Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -43.87%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Mersana Therapeutics's ROA excels beyond industry benchmarks, reaching -7.99%. This signifies efficient management of assets and strong financial health.
Debt Management: Mersana Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 0.91. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MRSN
